IP Library › Granted Patent US 7,888,491
Granted Patent B2
US 7,888,491 · App. 10/901,714 · Granted Feb 15, 2011

Outer membrane protein of

Assignee: The Ohio State University Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,888,491
App. No.
10/901,714
Granted
Feb 15, 2011
Kind
B2
Abstract

Diagnostic tools for for serodiagnosing ehrlichiosis in mammals, particularly in members of the Canidae family and in humans are provided. The diagnostic tools are a group of outer membrane proteins of E. chaffeensis and variants thereof, referred to hereinafter as the “OMP proteins”, a group of outer membrane proteins of E. canis and variants thereof referred to hereinafter as the “P30F proteins”, and antibodies to the OMP proteins and the P30F proteins. The OMP proteins of E. chaffeensis encompass OMP-1, OMP-1A, OMP1-B, OMP-1C, OMP1-D, OMP1-E, OMP1-F, OMP1-H, OMP-1R, OMP-1S, OMP-1T, OMP-1U, OMP-1V, OMP-1W, OMP-1X, OMP-1Y and OMP-1Z. The P30F proteins of E. canis encompass P30, P30a, P30-1, P30-2, P30-3, P304, P30-5, P30-6, P30-7, P30-8, P30-9, P30-10, P30-11, and P30-12. Isolated polynucleotides that encode the E. chaffeensis OMP proteins and isolated polynucleotides that encode the E. canis P30F protein are also provided. The present invention also relates to kits containing reagents for diagnosing human ehrlichiosis and canine ehrlichiosis, and to immunogenic compositions containing one or more OMP proteins or P30F proteins.

Claims (32)

1. An isolated or purified polypeptide comprising a sequence chosen from the following: a P30 protein, a variant of the P30 protein, an antigenic fragment of the P30 protein, wherein the P30 protein consists of SEQ ID NO. 32; a P30a protein, a variant of the P30a protein, an antigenic fragment of the P30a protein, wherein the P30a protein consists of SEQ ID NO. 34; a P30-1 protein, a variant of the p30-1 protein, an antigenic fragment of the P30-1 protein, wherein the P30-1 protein consists of SEQ ID NO. 36; a P30-2 protein, a variant of the P30-2 protein, an antigenic fragment of the P30-2 protein, wherein the P30-2 protein consists of SEQ ID NO. 38; a P30-3 protein, a variant of the P30-3 protein, an antigenic fragment of the P30-3 protein, wherein the P30-3 protein consists of SEQ ID NO. 40; a P30-4 protein, a variant of the P30-4 protein, an antigenic fragment of the P30-4 protein, wherein the P30-4 protein consists of SEQ ID NO. 42; a P30-5 protein, a variant of the P30-5 protein, an antigenic fragment of the P30-5 protein, wherein the P30-5 protein consists of SEQ ID NO. 44; a P30-6 protein, a variant of the P30-6 protein, an antigenic fragment of the P30-6 protein, wherein the P30-6 protein consists of SEQ ID NO. 54; a P30-7 protein, a variant of the P30-7 protein, an antigenic fragment of the P30-7 protein, wherein the P30-7 protein consists of SEQ ID NO. 56; a P30-8 protein, a variant of the P30-8 protein, an antigenic fragment of the P30-8 protein, wherein the P30-8 protein consists of SEQ ID NO. 46; a P30-9 protein, a variant of the P30-9 protein, an antigenic fragment of the P30-9 protein, wherein the P30-9 protein consists of SEQ ID NO. 58; a P30-10 protein, a variant of the P30-10 protein, an antigenic fragment of the P30-10 protein, wherein the P30-10 protein consists of SEQ ID NO. 48; a P30-11 protein, a variant of the P30-11 protein, an antigenic fragment of the P30-11 protein, wherein the P30-11 protein consists of SEQ ID NO. 60; a P30-12 protein, a variant of the P30-12 protein, and an antigenic fragment of the P30-12 protein, wherein the P30-12 protein consists of SEQ ID NO. 62; and wherein the variants or antigenic fragments of each said P30, P30a, P30-1, P30-2, P30-3, P30-4, P30-5, P30-6, P30-7, P30-8, P30-9, P30-10, P30-11, P30-12 protein are immunoreactive with at least one antibody that binds to their corresponding protein.

2. An isolated or purified polypeptide, wherein said polypeptide comprises a sequence that is at least 95% identical to an E. canis sequence chosen from: amino acid 26 through amino acid 288 of SEQ ID NO: 32, amino acid 26 through amino acid 287 of SEQ ID NO: 34, amino acid 55 through amino acid 307 of SEQ ID NO: 36, amino acid 26 through amino acid 280 of SEQ ID NO: 38, amino acid 26 through amino acid 283 of SEQ ID NO: 40, amino acid 26 through amino acid 276 of SEQ ID NO: 42, amino acid 27 through amino acid 293 of SEQ ID NO: 44, amino acid 31 through amino acid 293 of SEQ ID NO: 54, amino acid 31 through amino acid 296 of SEQ ID NO: 56, amino acid 27 through amino acid 299 of SEQ ID NO: 46, amino acid 27 through amino acid 281 of SEQ ID NO: 58, amino acid 26 through amino acid 280 of SEQ ID NO: 48, amino acid 26 through amino acid 279 of SEQ ID NO: 60, and amino acid 1 through amino acid 241 of SEQ ID NO: 62.

3. The isolated polypeptide of claim 1 wherein said polypeptide is the P30 protein, a variant of the P30 protein, or an antigenic fragment of the P30 protein.

4. An isolated polypeptide wherein said polypeptide comprises a sequence which is at least 95% identical to the sequence amino acid 33 through amino acid 224 of SEQ ID NO: 32.

5. The isolated polypeptide of claim 1 , wherein said polypeptide is the P30a protein, a variant of the P30a protein, or an antigenic fragment of the P30a protein.

6. The isolated polypeptide of claim 1 , wherein said polypeptide is the P30-1 protein, a variant of the P30-1 protein, or an antigenic fragment of the P30-1 protein.

7. The isolated polypeptide of claim 1 , wherein said polypeptide is the P30-2 protein, a variant of the P30-2 protein, or an antigenic fragment of the P30-2 protein.

8. The isolated polypeptide of claim 1 , wherein said polypeptide is the P30-3 protein, a variant of the P30-3 protein, or an antigenic fragment of the P30-3 protein.

9. The isolated polypeptide of claim 1 , wherein said polypeptide is the P30-4 protein, a variant of the P30-4 protein, or an antigenic fragment of the P30-4 protein.

10. The isolated polypeptide of claim 1 , wherein said polypeptide is the P30-5 protein, a variant of the P30-5 protein, or an antigenic fragment of the P30-5 protein.

11. The isolated polypeptide of claim 1 , wherein said polypeptide is the P30-6 protein, a variant of the P30-6 protein, or an antigenic fragment of the P30-6 protein.

12. The isolated polypeptide of claim 1 , wherein said polypeptide is the P30-7 protein, a variant of the P30-7 protein, or an antigenic fragment of the P30-7 protein.

13. The isolated polypeptide of claim 1 , wherein said polypeptide is the P30-8 protein, a variant of the P30-8 protein, or an antigenic fragment of the P30-8 protein.

14. The isolated polypeptide of claim 1 , wherein said polypeptide is the P30-9 protein, a variant of the P30-9 protein, or an antigenic fragment of the P30-9 protein.

15. The isolated polypeptide of claim 1 , wherein said polypeptide is the P30-10 protein, a variant of the P30-10 protein, or an antigenic fragment of the P30-10 protein.

16. The isolated polypeptide of claim 1 , wherein said polypeptide is the P30-11 protein, a variant of the P30-11 protein, or an antigenic fragment of the P30-11 protein.

17. The isolated polypeptide of claim 1 , wherein said polypeptide is the P30-12 protein, a variant of the P30-12 protein, or an antigenic fragment of the P30-12 protein.

18. The isolated or purified polypeptide of claim 2 , wherein said polypeptide comprises a sequence that is 100% identical to an E. canis sequence chosen from: amino acid 26 through amino acid 288 of SEQ ID NO: 32, amino acid 26 through amino acid 287 of SEQ ID NO: 34, amino acid 55 through amino acid 307 of SEQ ID NO: 36, amino acid 26 through amino acid 280 of SEQ ID NO: 38, amino acid 26 through amino acid 283 of SEQ ID NO: 40, amino acid 26 through amino acid 276 of SEQ ID NO: 42, amino acid 27 through amino acid 293 of SEQ ID NO: 44, amino acid 31 through amino acid 293 of SEQ ID NO: 54, amino acid 31 through amino acid 296 of SEQ ID NO: 56, amino acid 27 through amino acid 299 of SEQ ID NO: 46, amino acid 27 through amino acid 281 of SEQ ID NO: 58, amino acid 26 through amino acid 280 of SEQ ID NO: 48, amino acid 26 through amino acid 279 of SEQ ID NO: 60, and amino acid 1 through amino acid 241 of SEQ ID NO: 62.

19. The isolated or purified polypeptide of claim 18 , wherein said polypeptide comprises a sequence that is 100% identical to the sequence amino acid 26 through amino acid 288 of SEQ ID NO: 32.

20. The isolated or purified polypeptide of claim 18 , wherein said polypeptide comprises a sequence that is 100% identical to the sequence amino acid amino acid 26 through amino acid 287 of SEQ ID NO: 34.

21. The isolated or purified polypeptide of claim 18 , wherein said polypeptide comprises a sequence that is 100% identical to the sequence amino acid 55 through amino acid 307 of SEQ ID NO: 36.

22. The isolated or purified polypeptide of claim 18 , wherein said polypeptide comprises a sequence that is 100% identical to the sequence amino acid 26 through amino acid 280 of SEQ ID NO: 38.

23. The isolated or purified polypeptide of claim 18 , wherein said polypeptide comprises a sequence that is 100% identical to the sequence amino acid 26 through amino acid 283 of SEQ ID NO: 40.

24. The isolated or purified polypeptide of claim 18 , wherein said polypeptide comprises a sequence that is 100% identical to the sequence amino acid 26 through amino acid 276 of SEQ ID NO: 42.

25. The isolated or purified polypeptide of claim 18 , wherein said polypeptide comprises a sequence that is 100% identical to the sequence amino acid 27 through amino acid 293 of SEQ ID NO: 44.

26. The isolated or purified polypeptide of claim 18 , wherein said polypeptide comprises a sequence that is 100% identical to the sequence amino acid 31 through amino acid 293 of SEQ ID NO: 54.

27. The isolated or purified polypeptide of claim 18 , wherein said polypeptide comprises a sequence that is 100% identical to the sequence amino acid 31 through amino acid 296 of SEQ ID NO: 56.

28. The isolated or purified polypeptide of claim 18 , wherein said polypeptide comprises a sequence that is 100% identical to the sequence amino acid 27 through amino acid 299 of SEQ ID NO: 46.

29. The isolated or purified polypeptide of claim 18 , wherein said polypeptide comprises a sequence that is 100% identical to the sequence amino acid 27 through amino acid 281 of SEQ ID NO: 58.

30. The isolated or purified polypeptide of claim 18 , wherein said polypeptide comprises a sequence that is 100% identical to the sequence amino acid 26 through amino acid 280 of SEQ ID NO: 48.

31. The isolated or purified polypeptide of claim 18 , wherein said polypeptide comprises a sequence that is 100% identical to the sequence amino acid 26 through amino acid 279 of SEQ ID NO: 60.

32. The isolated or purified polypeptide of claim 18 , wherein said polypeptide comprises a sequence that is 100% identical to the sequence amino acid 1 through amino acid 241 of SEQ ID NO: 62.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 16, 2018
From: OHIO STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046546/0859 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2010
From: RIKIHISA, YASUKO; OHASHI, NORIO
To: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
Reel/Frame 023934/0910 →
Continuity (4)
Division 10314639 · Dec 9, 2002
Division 09314701 · May 19, 1999
Provisional Application 60100843 · Sep 18, 1998
Related Publication 20040265333A1 · Dec 30, 2004